다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Journal of Korean medical science : JKMS, v.21 no.1 = no.107, 2006년, pp.40 - 45
Kim, Min-Kyoung (Department of Medicine, Yeungnam University College of Medicine, Daegu, Korea.) , Lee, Jae-Lyun (Department of Internal Medicine, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea.) , Cho, Hee Soon (Department of Diagnostic Laboratory Medicine, Yeungnam University College of Medicine, Daegu, Korea.) , Bae, Sung Hwa (Department of Medicine, Daegu Catholic University College of Medicine, Daegu, Korea.) , Ryoo, Hun Mo (Department of Medicine, Daegu Catholic University College of Medicine, Daegu, Korea.) , Lee, Kyung Hee (Department of Medicine, Yeungnam University College of Medicine, Daegu, Korea.) , Hyun, Myung Soo (Department of Medicine, Yeungnam University College of Medicine, Daegu, Korea.)
AI-Helper
TNF-α mediated apoptosis of the hematopoietic cells has been thought to contribute to the ineffective hematopoiesis observed in myelodysplastic syndrome (MDS). The combination of pentoxifylline (P) and ciprofloxacin (C) has been shown to reduce the serum levels of TNF-α, and an earlier t...
1 Heaney ML Golde DW Myelodysplasia N Engl J Med 1999 340 1649 1660 10341278
2 Gersuk GM Beckham C Loken MR Kiener P Anderson JE Farrand A Troutt AB Ledbetter JA Deeg HJ A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome Br J Haematol 1998 103 176 188 9792306
3 Allampallam K Shetty VT Raza A Cytokines and MDS Cancer Treat Res 2001 108 93 100 11702608
4 Broxmeyer HE Williams DE Lu L Cooper S Anderson SL Beyer GS Hoffman R Rubin BY The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma J Immunol 1986 136 4487 4495 3086433
5 Roodman GD Bird A Hutzler D Montgomery W Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells Exp Hematol 1987 15 928 935 2820776
6 Means RT Jr Krantz SB Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon J Clin Invest 1993 91 416 419 8432849
7 Sato T Selleri C Anderson S Young NS Maciejewski JP Expression and modulation of cellular receptors for interferon-gamma, tumour necrosis factor, and Fas on human bone marrow CD34+ cells Br J Haematol 1997 97 356 365 9163602
8 Sawanobori M Yamaguchi S Hasegawa M Inoue M Suzuki K Kamiyama R Hirokawa K Kitagawa M Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes Leuk Res 2003 27 583 591 12681357
9 Mundle SD Reza S Ali A Mativi Y Shetty V Venugopal P Gregory SA Raza A Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes Cancer Lett 1999 140 201 207 10403560
10 Peddie CM Wolf CR McLellan LI Collins AR Bowen DT Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration Br J Haematol 1997 99 625 631 9401076
11 Raza A Venugopal P Genzer S Hiddemann W Buchner T Wormann B Pilot study of pentoxifylline and ciprofloxacin with or without dexamethasone produces encouraging results in myelodysplastic syndromes: acute leukemias VII Experimental Approaches and Novel Therapies 1998 New York Springer-Verlag 42 51
12 Raza A Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes Microsc Res Tech 2000 50 229 235 10891888
13 Bennett JM Catovsky D Daniel MT Flandrin G Galton DA Gralnick HR Sultan C Proposals for the classification of the myelodysplastic syndromes Br J Haematol 1982 51 189 199 6952920
14 Harris NL Jaffe ES Diebold J Flandrin G Muller-Hermelink HK Vardiman J Lister TA Bloomfield CD World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997 J Clin Oncol 1999 17 3835 3849 10577857
15 Greenberg P Cox C LeBeau MM Fenaux P Morel P Sanz G Sanz M Vallespi T Hamblin T Oscier D Ohyashiki K Toyama K Aul C Mufti G Bennett J International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 1997 89 2079 2088 9058730
16 Cheson BD Bennett JM Kantarjian H Pinto A Schiffer CA Nimer SD Lowenberg B Beran M de Witte TM Stone RM Mittelman M Sanz GF Wijermans PW Gore S Greenberg PL World Health Organization (WHO) international working group Report of an international working group to standardize response criteria for myelodysplastic syndromes Blood 2000 96 3671 3674 11090046
17 Raza A Meyer P Dutt D Zorat F Lisak L Nascimben F du Randt M Kaspar C Goldberg C Loew J Dar S Gezer S Venugopal P Zeldis J Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes Blood 2001 98 958 965 11493439
18 List AF Brasfield F Heaton R Glinsmann-Gibson B Crook L Taetle R Capizzi R Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome Blood 1997 90 3364 3369 9345018
19 Deeg HJ Gotlib J Beckham C Dugan K Holmberg L Schubert M Appelbaum F Greenberg P Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study Leukemia 2002 16 162 164 11840280
20 Raza A Qawi H Andric T Dar S Lisak L Huang RW Venugopal P Gezer S Gregory SA Hsu WT Loew J Robin E Rifkin S Shah R Divgi A Taylor R Grosset A Pentoxifylline, ciprofloxacin and dexamethasone improve the ineffective hematopoiesis in myelodysplastic syndrome patients; malignancy Hematology 2000 5 275 284 11399622
21 Raza A Qawi H Lisak L Andric T Dar S Andrews C Venugopal P Gezer S Gregory S Loew J Robin E Rifkin S Hsu WT Huang RW Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone Blood 2000 95 1580 1587 10688811
22 Maciejewski JP Risitano AM Sloand EM Wisch L Geller N Barrett JA Young NS A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome Br J Haematol 2002 117 119 126 11918541
23 Deeg HJ Jiang PY Holmberg LA Scott B Petersdorf EW Appelbaum FR Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells Leuk Res 2004 28 1177 1180 15380342
24 Raza A Candoni A Khan U Lisak L Tahir S Silvestri F Billmeier J Alvi MI Mumtaz M Gezer S Venugopal P Reddy P Galili N Remicade as TNF suppressor in patients with myelodysplastic syndromes Leuk Lymphoma 2004 45 2099 2104 15370256
25 Daskalakis M Nguyen TT Nguyen C Guldberg P Kohler G Wijermans P Jones PA Lubbert M Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment Blood 2002 100 2957 2964 12351408
26 Kurzrock R Albitar M Cortes JE Estey EH Faderl SH Garcia-Manero G Thomas DA Giles FJ Ryback ME Thibault A De Porre P Kantarjian HM Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome J Clin Oncol 2004 22 1287 1292 15051776
27 List A Beran M DiPersio J Slack J Vey N Rosenfeld CS Greenberg P Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes Leukemia 2003 17 1499 1507 12886236
28 Silverman LR Demakos EP Peterson BL Kornblith AB Holland JC Odchimar-Reissig R Stone RM Nelson D Powell BL DeCastro CM Ellerton J Larson RA Schiffer CA Holland JF Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J Clin Oncol 2002 20 2429 2440 12011120
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.